We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Intellia Therapeutics, Inc. (NTLA - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Intellia Therapeutics, Inc. is a member of the Medical sector. This group includes 959 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Intellia Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for NTLA's full-year earnings has moved 3.6% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, NTLA has moved about 75.3% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 1.5% on a year-to-date basis. This means that Intellia Therapeutics, Inc. is outperforming the sector as a whole this year.
Another stock in the Medical sector, Akebia Therapeutics (AKBA - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 55.3%.
In Akebia Therapeutics' case, the consensus EPS estimate for the current year increased 100% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Intellia Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 471 individual stocks and currently sits at #90 in the Zacks Industry Rank. On average, stocks in this group have gained 8.6% this year, meaning that NTLA is performing better in terms of year-to-date returns.
Akebia Therapeutics, however, belongs to the Medical - Drugs industry. Currently, this 147-stock industry is ranked #78. The industry has moved +9.6% so far this year.
Investors with an interest in Medical stocks should continue to track Intellia Therapeutics, Inc. and Akebia Therapeutics. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Intellia Therapeutics, Inc. (NTLA - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Intellia Therapeutics, Inc. is a member of the Medical sector. This group includes 959 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Intellia Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for NTLA's full-year earnings has moved 3.6% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, NTLA has moved about 75.3% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 1.5% on a year-to-date basis. This means that Intellia Therapeutics, Inc. is outperforming the sector as a whole this year.
Another stock in the Medical sector, Akebia Therapeutics (AKBA - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 55.3%.
In Akebia Therapeutics' case, the consensus EPS estimate for the current year increased 100% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Intellia Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 471 individual stocks and currently sits at #90 in the Zacks Industry Rank. On average, stocks in this group have gained 8.6% this year, meaning that NTLA is performing better in terms of year-to-date returns.
Akebia Therapeutics, however, belongs to the Medical - Drugs industry. Currently, this 147-stock industry is ranked #78. The industry has moved +9.6% so far this year.
Investors with an interest in Medical stocks should continue to track Intellia Therapeutics, Inc. and Akebia Therapeutics. These stocks will be looking to continue their solid performance.